Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

What benefit could be derived from on-line adaptive prostate radiotherapy using rectal diameter as a predictor of motion?

Oates R, Gill S, Foroudi F, Joon ML, Schneider M, Bressel M, Kron T.

J Med Phys. 2015 Jan-Mar;40(1):18-23. doi: 10.4103/0971-6203.152237.

2.

Ten-year results of quality assurance in radiotherapy chart round.

Taghavi Bayat B, Gill S, Siva S, Tai KH, Joon ML, Foroudi F.

BMC Health Serv Res. 2013 Apr 23;13:148. doi: 10.1186/1472-6963-13-148.

3.

The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer.

Mak D, Joon DL, Chao M, Wada M, Joon ML, See A, Feigen M, Jenkins P, Mercuri A, McNamara J, Poon A, Khoo V.

Radiother Oncol. 2010 Nov;97(2):205-11. doi: 10.1016/j.radonc.2010.05.016. Epub 2010 Jul 1.

PMID:
20598390
4.

Assessing the impact of FDG-PET in the management of anal cancer.

Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A.

Radiother Oncol. 2008 Jun;87(3):376-82. doi: 10.1016/j.radonc.2008.04.003. Epub 2008 Apr 29.

PMID:
18453023
5.

Towards individualised radiotherapy for Stage I seminoma.

Martin JM, Joon DL, Ng N, Grace M, Gelderen DV, Lawlor M, Wada M, Joon ML, Quong G, Khoo V.

Radiother Oncol. 2005 Sep;76(3):251-6.

PMID:
16169622
6.

Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre study.

Gyorki DE, Ainslie J, Joon ML, Henderson MA, Millward M, McArthur GA.

Melanoma Res. 2004 Jun;14(3):223-30.

PMID:
15179193
7.

Primary adenocarcinoma of the anus: a retrospective analysis.

Joon DL, Chao MW, Ngan SY, Joon ML, Guiney MJ.

Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1199-205.

PMID:
10613313

Supplemental Content

Support Center